Michael, it's important to distinguish between tests looking for TB antibodies (which is what this report is about), and T-cell based, interferon-Gamma tests (QFT-G).
They are very different, so this report really serves to emphasize the weaknesses of the competition faced by Cellestis. Far from being a negative for CST, it's probably a Buy signal!
